Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 04, 2020 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | OptimizeRx Corp | |
Entity Central Index Key | 0001448431 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2020 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity File Number | 001-38543 | |
Entity Emerging Growth Company | false | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding | 14,646,747 | |
Entity Incorporation State Country Code | NV |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Current Assets | ||
Cash and cash equivalents | $ 15,210,069 | $ 18,852,680 |
Accounts receivable, net | 9,061,520 | 7,418,025 |
Prepaid expenses | 3,035,205 | 871,043 |
Total Current Assets | 27,306,794 | 27,141,748 |
Property and equipment, net | 170,123 | 176,014 |
Other Assets | ||
Goodwill | 14,740,031 | 14,740,031 |
Technology assets, net | 5,980,607 | 6,238,453 |
Patent Rights, net | 2,496,498 | 2,550,587 |
Right of use assets, net | 531,844 | 559,863 |
Other intangible assets, net | 4,993,215 | 5,151,102 |
Security deposits and other assets | 16,013 | 80,727 |
Total Other Assets | 28,758,208 | 29,320,763 |
TOTAL ASSETS | 56,235,125 | 56,638,525 |
Current Liabilities | ||
Accounts payable - trade | 548,100 | 492,995 |
Accrued expenses | 1,674,477 | 1,800,635 |
Revenue share payable | 2,640,249 | 1,618,438 |
Current portion of lease obligations | 117,479 | 115,431 |
Current portion of contingent purchase price payable | 4,000,000 | 1,500,000 |
Deferred revenue | 491,438 | 580,014 |
Total Current Liabilities | 9,471,743 | 6,107,513 |
Non-current Liabilities | ||
Lease obligations, net of current portion | 418,390 | 448,753 |
Contingent purchase price payable, net of current portion | 2,720,000 | 5,220,000 |
Total Non-current liabilities | 3,138,390 | 5,668,753 |
Total Liabilities | 12,610,133 | 11,776,266 |
Commitments and contingencies (See note 7) | ||
Stockholders' Equity | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at March 31, 2020 or December 31, 2019 | ||
Common stock, $0.001 par value, 166,666,667 shares authorized, 14,646,747 and 14,600,579 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | 14,647 | 14,601 |
Additional paid-in-capital | 79,238,886 | 78,272,268 |
Accumulated deficit | (35,628,541) | (33,424,610) |
Total Stockholders' Equity | 43,624,992 | 44,862,259 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 56,235,125 | $ 56,638,525 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 166,666,667 | 166,666,667 |
Common stock, shares issued | 14,646,747 | 14,600,579 |
Common stock, shares outstanding | 14,646,747 | 14,600,579 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
NET REVENUE | ||
TOTAL REVENUE | $ 7,584,602 | $ 5,209,434 |
COST OF REVENUES | 3,241,763 | 1,583,480 |
GROSS MARGIN | 4,342,839 | 3,625,954 |
OPERATING EXPENSES | 6,602,091 | 3,493,789 |
INCOME (LOSS) FROM OPERATIONS | (2,259,252) | 132,165 |
OTHER INCOME (EXPENSE) | ||
Interest Income | 55,321 | 22,364 |
Change in Fair Value of Contingent Consideration | (148,000) | |
Interest (Expense) | ||
TOTAL OTHER INCOME (EXPENSE) | 55,321 | (125,636) |
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES | (2,203,931) | 6,529 |
NET INCOME (LOSS) | $ (2,203,931) | $ 6,529 |
WEIGHTED AVERAGE SHARES OUTSTANDING | ||
BASIC | 14,609,499 | 12,077,829 |
DILUTED | 14,609,499 | 13,077,917 |
NET LOSS PER SHARE | ||
BASIC | $ (0.15) | $ 0 |
DILUTED | $ (0.15) | $ 0 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($) | Common Stock | Additional Paid in Capital | Accumulated Deficit | Total |
Balance at Dec. 31, 2018 | $ 12,039 | $ 48,725,211 | $ (30,278,805) | $ 18,458,445 |
Balance, shares at Dec. 31, 2018 | 12,038,618 | |||
Cumulative effect of change in accounting principle related to lease accounting | (3,229) | (3,229) | ||
Shares issued for restricted stock awards | $ 130 | (130) | ||
Shares issued for restricted stock awards, shares | 130,001 | |||
Shares issued for stock options exercised | $ 102 | 343,683 | 343,785 | |
Shares issued for stock options exercised, shares | 101,878 | |||
Shares issued as compensation | $ 8 | 106,026 | 106,034 | |
Shares issued as compensation, shares | 8,336 | |||
Stock-based compensation expense | 530,312 | 530,312 | ||
Net income loss | 6,529 | 6,529 | ||
Balance at Mar. 31, 2019 | $ 12,279 | 49,705,102 | (30,275,505) | 19,441,876 |
Balance, shares at Mar. 31, 2019 | 12,278,833 | |||
Balance at Dec. 31, 2019 | $ 14,601 | 78,272,268 | (33,424,610) | 44,862,259 |
Balance, shares at Dec. 31, 2019 | 14,600,579 | |||
Shares issued as board compensation | $ 11 | 99,989 | 100,000 | |
Shares issued as board compensation, shares | 11,136 | |||
Shares issued for stock options exercised | $ 35 | 112,117 | 112,152 | |
Shares issued for stock options exercised, shares | 35,032 | |||
Stock-based compensation expense | 754,512 | 754,512 | ||
Net income loss | (2,203,931) | (2,203,931) | ||
Balance at Mar. 31, 2020 | $ 14,647 | $ 79,238,886 | $ (35,628,541) | $ 43,624,992 |
Balance, shares at Mar. 31, 2020 | 14,646,747 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net Income (loss) | $ (2,203,931) | $ 6,529 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
Depreciation, amortization and non-cash lease expense | 519,669 | 190,301 |
Stock-based compensation | 754,512 | 530,312 |
Stock issued for board service | 100,000 | 106,034 |
Change in fair value of contingent consideration | 148,000 | |
Changes in: | ||
Accounts receivable | (1,643,495) | 1,554,953 |
Prepaid expenses and other assets | (2,099,448) | (44,201) |
Accounts payable | 55,105 | 173,810 |
Revenue share payable | 1,021,811 | (776,514) |
Accrued expenses and other liabilities | (154,473) | (1,034,454) |
Deferred revenue | (88,576) | 35,199 |
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | (3,738,826) | 889,969 |
CASH FLOWS USED IN INVESTING ACTIVITIES: | ||
Purchase of equipment | (15,937) | (13,848) |
NET CASH USED IN INVESTING ACTIVITIES | (15,937) | (13,848) |
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES: | ||
Proceeds from exercise of stock options | 112,152 | 343,785 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 112,152 | 343,785 |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (3,642,611) | 1,219,906 |
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD | 18,852,680 | 8,914,034 |
CASH AND CASH EQUIVALENTS - END OF PERIOD | 15,210,069 | 10,133,940 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||
Cash paid for interest | ||
Cash paid for income taxes | ||
Non-cash effect of cumulative adjustments to accumulated deficit | 3,229 | |
Lease liabilities arising from right of use assets | $ 207,559 |
Nature of Business and Basis of
Nature of Business and Basis of Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF BUSINESS AND BASIS OF PRESENTATION | NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include OptimizeRx Corporation and its wholly owned subsidiaries (collectively, the "Company", "we", "our", or "us"). We are a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science clients, our suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. Our network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider's workflow through leading electronic health platforms. Our fully integrated platform ensures the real-time exchange of information—connecting care to improve provider knowledge and patient engagement. The condensed consolidated financial statements for the three months ended March 31, 2020 and 2019 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position at March 31, 2020, and our results of operations, changes in stockholders' equity, and cash flows for the three months ended March 31, 2020 and 2019, have been made. Those adjustments consist of normal and recurring adjustments. The condensed consolidated condensed balance sheet as of December 31, 2019, has been derived from the audited consolidated condensed balance sheet as of that date. Certain information and note disclosures, including a detailed discussion about the Company's significant accounting policies, normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the U.S. Securities and Exchange Commission on March 26, 2020. The results of operations for the three-months ended March 31, 2020, are not necessarily indicative of the results to be expected for the full year. |
New Accounting Standards
New Accounting Standards | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Changes and Error Corrections [Abstract] | |
NEW ACCOUNTING STANDARDS | NOTE 2 – NEW ACCOUNTING STANDARDS In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 provides for a new impairment model that requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to accounts receivable and available for sale debt securities. ASU 2016-13 was effective for the Company on January 1, 2020. The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows. In August 2019, the FASB issued ASU 2019-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2019-13 modifies the disclosure requirements on fair value measurements and became effective for the Company on January 1, 2020. The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment test. The second step measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. Under ASU 2017-04, a company will record an impairment charge based on the excess of a reporting unit's carrying amount over its fair value. ASU 2017-04 will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
LEASES | NOTE 3 – LEASES We have operating leases for office space in three multitenant facilities with lease terms greater than 12 months, which are recorded as assets and liabilities on our balance sheet. These leases include our corporate headquarters, located in Rochester, Michigan, a customer service facility in Cranbury, New Jersey, and a technical facility in Zagreb, Croatia. Certain leases contain renewal options and for the headquarters lease, we have assumed renewal. Lease-related assets, or right-of-use assets, are recognized at the lease commencement date at amounts equal to the respective lease liabilities, adjusted for prepaid lease payments, initial direct costs, and lease incentives received. Lease-related liabilities are recognized at the present value of the remaining contractual fixed lease payments, discounted using our incremental borrowing rate. Amortization of the right of use assets is recognized as non-cash lease expense on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Short term lease costs include month to month leases in shared office space facilities, such as WeWork, or similar locations. For the three months ended March 31, 2020 and 2019, the Company's lease cost consists of the following components, each of which is included in operating expenses within the Company's condensed consolidated statements of operations: Three Months Three Months Operating lease cost $ 32,814 $ 30,684 Short-term lease cost 44,629 9,841 Total lease cost $ 77,443 $ 40,525 The table below presents the future minimum lease payments to be made under operating leases as of March 31, 2020: As of March 31, 2020 2020(a) $ 103,603 2021 140,367 2022 102,367 2023 99,209 2024 80,375 Thereafter 70,224 Total 596,145 Less: discount 60,276 Total lease liabilities $ 535,869 (a) For the nine-month period beginning April 1, 2020. The weighted average remaining lease term at March 31, 2020 for operating leases is 4.9 years and the weighted average discount rate used in calculating the operating lease asset and liability is 4.5%. Cash paid for amounts included in the measurement of lease liabilities was $28,316 and $30,684 for the three months ending March 31, 2020 and 2019, respectively. For the three months ended March 31, 2020 and 2019, payments on lease obligations were $34,416 and $25,208, respectively, and amortization on the right of use assets was $28,019 and $25,245, respectively. |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
STOCKHOLDERS’ EQUITY | NOTE 4 – STOCKHOLDERS' EQUITY During the quarters ended March 31, 2020 and 2019, we issued 11,136 and 8,336 shares, respectively, of our common stock to our independent directors in connection with our Director Compensation Plan. These shares were valued at $100,000 and $106,834 at March 31, 2020 and 2019, respectively. During the quarter ended March 31, 2020, we issued 35,032 shares of our common stock and received proceeds of $112,152 in connection with the exercise of stock options under our 2013 equity compensation plan. During the quarter ended March 31, 2019, we issued 89,826 shares of our common stock and received proceeds of $343,785 in connection with the exercise of stock options under our 2013 equity compensation plan. We issued an additional 12,052 shares of our common stock in connection with the exercise of options using the net-settled method, which resulted in no cash received, but rather the exercise price was paid by the surrender of shares underlying the options. We also issued 130,001 shares of our common stock in the quarter ended March 31, 2019 in connection with restricted stock awards awarded in 2018. |
Share Based Payments - Options
Share Based Payments - Options and Restricted Stock | 3 Months Ended |
Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
SHARE BASED PAYMENTS - OPTIONS AND RESTRICTED STOCK | NOTE 5 – SHARE BASED PAYMENTS – OPTIONS AND RESTRICTED STOCK We use the fair value method to account for stock-based compensation. We recorded $547,828 and $530,312 in compensation expense in the three months ended March 31, 2020 and 2019, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current period as well as options issued in the current period. The fair value of these instruments was calculated using the Black-Scholes option pricing model. There is $2,185,349 of remaining expense related to unvested options to be recognized in the future over a weighted average period of 1.6 years. The total intrinsic value of outstanding options at March 31, 2020 was $6,810,214. We also recorded $206,684 in compensation expense related to restricted stock awards that vest over time in the three months ended March 31, 2020. There is $1,245,841 of remaining expense related to unvested restricted stock awards to be recognized in the future over a weighted average period of 2.8 years. |
Net Income (Loss) per Share
Net Income (Loss) per Share | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
NET INCOME (LOSS) PER SHARE | NOTE 6 – NET INCOME (LOSS) PER SHARE The following table sets forth the computation of basic and diluted net income (loss) per share. Three Months Ended 2020 2019 Numerator Net Income (Loss) $ (2,203,931 ) $ 6,529 Denominator Weighted average shares outstanding used in computing net income (loss) per share Basic 14,609,499 12,077,829 Effect of dilutive stock options, warrants, and stock grants - 1,000,088 Diluted 14,609,499 13,077,917 Net Income (Loss) per share Basic $ (0.15 ) $ 0.00 Diluted $ (0.15 ) $ 0.00 No calculation of diluted earnings per share is included for 2020 as the effect of the calculation would be antidilutive. The number of common shares potentially issuable upon the exercise of certain options that were excluded from the diluted loss per common share calculation in 2020 was 779,670 related to options, and 174,176 related to restricted stock, for a total of 953,846. |
Contingencies
Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
CONTINGENCIES | NOTE 7 – CONTINGENCIES Litigation The Company is not currently involved in any legal proceedings. COVID-19 Due to the COVID |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2020 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 8 – SUBSEQUENT EVENTS In accordance with ASC 855-10, we have analyzed our operations subsequent to March 31, 2020 through the date these financial statements were issued and have determined that we do not have any material subsequent events to disclose or recognize in these financial statements. |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Schedule of lease cost | Three Months Three Months Operating lease cost $ 32,814 $ 30,684 Short-term lease cost 44,629 9,841 Total lease cost $ 77,443 $ 40,525 |
Schedule of future minimum lease payments | As of March 31, 2020 2020(a) $ 103,603 2021 140,367 2022 102,367 2023 99,209 2024 80,375 Thereafter 70,224 Total 596,145 Less: discount 60,276 Total lease liabilities $ 535,869 (a) For the nine-month period beginning April 1, 2020. |
Net Income (Loss) per Share (Ta
Net Income (Loss) per Share (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Schedule of basic and diluted net income (loss) per share | Three Months Ended 2020 2019 Numerator Net Income (Loss) $ (2,203,931 ) $ 6,529 Denominator Weighted average shares outstanding used in computing net income (loss) per share Basic 14,609,499 12,077,829 Effect of dilutive stock options, warrants, and stock grants - 1,000,088 Diluted 14,609,499 13,077,917 Net Income (Loss) per share Basic $ (0.15 ) $ 0.00 Diluted $ (0.15 ) $ 0.00 |
Leases (Details)
Leases (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Leases [Abstract] | ||
Operating lease cost | $ 32,814 | $ 30,684 |
Short-term lease cost | 44,629 | 9,841 |
Total lease cost | $ 77,443 | $ 40,525 |
Leases (Details 1)
Leases (Details 1) | Mar. 31, 2020USD ($) | |
Leases [Abstract] | ||
2020 | $ 103,603 | [1] |
2021 | 140,367 | |
2022 | 102,367 | |
2023 | 99,209 | |
2024 | 80,375 | |
Thereafter | 70,224 | |
Total | 596,145 | |
Less: discount | 60,276 | |
Total lease liabilities | $ 535,869 | |
[1] | For the nine-month period beginning April 1, 2020. |
Leases (Details Textual)
Leases (Details Textual) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Leases (Textual) | ||
Weighted average remaining lease term | 4 years 10 months 25 days | |
Weighted average discount rate | 4.50% | |
Measurement of lease liabilities | $ 28,316 | $ 30,684 |
Payments on lease obligations | 34,416 | 25,208 |
Amortization right of use assets | $ 28,019 | $ 25,245 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Stockholders' Equity (Textual) | ||
Net proceeds issuance of common stock | $ 112,152 | $ 343,785 |
Issued shares of common stock in connection with cashless exercise | 35,032 | 89,826 |
Compensation plan issuance of shares | 12,052 | |
Restricted common stock awards, shares | 130,001 | |
Independent Directors [Member] | ||
Stockholders' Equity (Textual) | ||
Shares of common stock issued | 11,136 | 8,336 |
Shares of common stock issued, value | $ 100,000 | $ 106,834 |
Share Based Payments - Option_2
Share Based Payments - Options and Restricted Stock (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Share Based Payments - Options and Restricted Stock (Textual) | ||
Weighted average contractual life | 1 year 7 months 6 days | |
Expense remaining to be recognized related to unvested options | $ 2,185,349 | |
Intrinsic value of outstanding options | 6,810,214 | |
Stock Compensation Plan [Member] | ||
Share Based Payments - Options and Restricted Stock (Textual) | ||
Stock compensation recognized expense | 547,828 | $ 530,312 |
Restricted Stock Awards [Member] | ||
Share Based Payments - Options and Restricted Stock (Textual) | ||
Stock compensation recognized expense | $ 206,684 | |
Weighted average contractual life | 2 years 9 months 18 days | |
Expense remaining to be recognized related to unvested options | $ 1,245,841 |
Net Income (Loss) per Share (De
Net Income (Loss) per Share (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Numerator | ||
Net Income (Loss) | $ (2,203,931) | $ 6,529 |
Weighted average shares outstanding used in computing net income (loss) per share | ||
Basic | 14,609,499 | 12,077,829 |
Effect of dilutive stock options, warrants, and stock grants | 1,000,088 | |
Diluted | 14,609,499 | 13,077,917 |
Net Income (Loss) per share | ||
Basic | $ (0.15) | $ 0 |
Diluted | $ (0.15) | $ 0 |
Net Income (Loss) per Share (_2
Net Income (Loss) per Share (Details Textual) | 3 Months Ended |
Mar. 31, 2020shares | |
Net Income (Loss) per Share (Textual) | |
Diluted loss per common share | 953,846 |
Restricted Stock [Member] | |
Net Income (Loss) per Share (Textual) | |
Diluted loss per common share | 174,176 |
Options [Member] | |
Net Income (Loss) per Share (Textual) | |
Diluted loss per common share | 779,670 |